A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884 on ClinicalTrials.gov · last registry update 2026-08-06
An unusually large phase 3: 1,000 participants, more than double the 424 typical for the stage. Due to report March 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Incontinence Episode Frequency (IEF). Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- RECRUITING
- Phase
- P3
- Drug
- orforglipronFoundayo
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 1,000
- Started
- 2025-09-30
- Primary completion
- 2028-03 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Incontinence Episode Frequency (IEF)
Conditions studied
Urinary Incontinence,Stress
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.